Induction of resistance to tuberculosis in mice with defined components of mycobacteria and with some unrelated materials

Ribi, Edgar; Granger, Donald L.; Milner, Kelsey C.; Strain, S. M.; Parker, R.; Smith, Robert W.; Brehmer, W; Azuma, Ichiro

doi:10.1016/s0174-3031(82)80104-2

Cited by 14 publications

(20 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It could possibly be due to the nonconjugation of their glycolipids with carrier proteins. Immunization of mice with cord factor-MBSA complexes [20] or P3 (a trehalose mycolate similar to cord factor), along with tuberculoprotein/some unrelated antigens such as BSA [41], have been demonstrated to mediate significant protection against challenge with M. tuberculosis, similar to the present study.…”

Section: Discussionsupporting

confidence: 82%

Protective immunity to experimental tuberculosis by mannophosphoinositides of mycobacteria

Mehta

Khuller

1988

Med Microbiol Immunol

View full text Add to dashboard Cite

Mannophosphoinositides isolated from mycobacterial cells were found to induce both humoral and cell-mediated immune responses in mice when injected as mannoside-methylated bovine serum albumin (MBSA) complexes. Immunization of mice with mannoside-MBSA complexes elicited significant protection against challenge with LDso dose of M. tuberculosis H37Rv as revealed by high survival rate, low values of root-specific lung weight, lung densities and colony forming units recovered from lung, liver and spleen, compared to the nonimmunized group. These observations were further substantiated by histopathological studies. The protective immunity elicited by mannoside-MBSA complexes against challenge with 3/. tuberculosis H37Rv was mediated by the cooperation of T-B ceils, as shown by the passive transfer of immune ceUs/sera' into syngeneic sublethally irradiated recipient mice.

show abstract

Section: Discussionsupporting

confidence: 82%

Protective immunity to experimental tuberculosis by mannophosphoinositides of mycobacteria

Mehta

Khuller

1988

Med Microbiol Immunol

View full text Add to dashboard Cite

show abstract

“…(173, 174)]. Whereas older adjuvant formulations relied on the use of cell wall extracts in liposomes or oil droplets (175, 176), modern adjuvants for TB vaccines target stimulation of PRRs including TLRs and MINCLE (174, 177). Adjuvants include cationic lipids, micro-/nanoparticles, toxin derivatives, CpG-containing DNA-based molecules, mycobacterial proteins conjugates, cytokines, and antimicrobial proteins (174).…”

Section: Adjuvants and Bcgmentioning

confidence: 99%

Immune Responses to Bacillus Calmette–Guérin Vaccination: Why Do They Fail to Protect against Mycobacterium tuberculosis?

2017

View full text Add to dashboard Cite

Mycobacterium tuberculosis (M.tb), the causative agent of tuberculosis (TB), is the current leading cause of death due to a single infectious organism. Although curable, the broad emergence of multi-, extensive-, extreme-, and total-drug resistant strains of M.tb has hindered eradication efforts of this pathogen. Furthermore, computational models predict a quarter of the world’s population is infected with M.tb in a latent state, effectively serving as the largest reservoir for any human pathogen with the ability to cause significant morbidity and mortality. The World Health Organization has prioritized new strategies for improved vaccination programs; however, the lack of understanding of mycobacterial immunity has made it difficult to develop new successful vaccines. Currently, Mycobacterium bovis bacillus Calmette–Guérin (BCG) is the only vaccine approved for use to prevent TB. BCG is highly efficacious at preventing meningeal and miliary TB, but is at best 60% effective against the development of pulmonary TB in adults and wanes as we age. In this review, we provide a detailed summary on the innate immune response of macrophages, dendritic cells, and neutrophils in response to BCG vaccination. Additionally, we discuss adaptive immune responses generated by BCG vaccination, emphasizing their specific contributions to mycobacterial immunity. The success of future vaccines against TB will directly depend on our understanding of mycobacterial immunity.

show abstract

“…A number of TDM analogues were synthesized for structure–activity studies, and some attenuation of TDM’s toxicity was possible while still retaining adjuvant activity [94]. TDM augments both humoral and cell-mediated immune responses when combined with vaccine antigens, with a comparable efficacy to MDP [95–97]. TDM is a component of the commercial veterinary Ribi Aduvant System ® (Sigma, USA) where it is formulated with squalene oil, monophosphoryl lipid A (MPL) and other components [96,97], but given its reactogenicity is unsuitable for inclusion in human vaccines.…”

Section: Mycobacterial Carbohydrate Adjuvant Compoundsmentioning

confidence: 99%

Carbohydrate-based immune adjuvants

Petrovsky

Cooper

2011

Expert Review of Vaccines

136

102

View full text Add to dashboard Cite

The role for adjuvants in human vaccines has been a matter of vigorous scientific debate, with the field hindered by the fact that for over 80 years, aluminum salts were the only adjuvants approved for human use. To this day, alum-based adjuvants, alone or combined with additional immune activators, remain the only adjuvants approved for use in the USA. This situation has not been helped by the fact that the mechanism of action of most adjuvants has been poorly understood. A relative lack of resources and funding for adjuvant development has only helped to maintain alum’s relative monopoly. To seriously challenge alum’s supremacy a new adjuvant has many major hurdles to overcome, not least being alum’s simplicity, tolerability, safety record and minimal cost. Carbohydrate structures play critical roles in immune system function and carbohydrates also have the virtue of a strong safety and tolerability record. A number of carbohydrate compounds from plant, bacterial, yeast and synthetic sources have emerged as promising vaccine adjuvant candidates. Carbohydrates are readily biodegradable and therefore unlikely to cause problems of long-term tissue deposits seen with alum adjuvants. Above all, the Holy Grail of human adjuvant development is to identify a compound that combines potent vaccine enhancement with maximum tolerability and safety. This has proved to be a tough challenge for many adjuvant contenders. Nevertheless, carbohydrate-based compounds have many favorable properties that could place them in a unique position to challenge alum’s monopoly over human vaccine usage.

show abstract

Induction of resistance to tuberculosis in mice with defined components of mycobacteria and with some unrelated materials

Cited by 14 publications

References 31 publications

Protective immunity to experimental tuberculosis by mannophosphoinositides of mycobacteria

Protective immunity to experimental tuberculosis by mannophosphoinositides of mycobacteria

Immune Responses to Bacillus Calmette–Guérin Vaccination: Why Do They Fail to Protect against Mycobacterium tuberculosis?

Carbohydrate-based immune adjuvants

Contact Info

Product

Resources

About